Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 149 clinical trials
featured
Newly Diagnosed Mantle Cell Lymphoma who are not eligible for a bone marrow transplant.

Newly Diagnosed Mantle Cell Lymphoma who are not eligible for a bone marrow transplant.

  • 834 views
  • 08 Nov, 2020
  • 1 location
featured
A Study of the Kinetics of Lymphoid Cells in Patients with Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers

Background: Chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL) are types of cancers in which there are too many

lymphoma
lymphocytosis
cancer
chronic lymphocytic leukemia
mantle cell lymphoma
  • 102 views
  • 15 Apr, 2019
  • 1 location
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell

acalabrutinib
bendamustine
rituximab
cyclin d1
  • 1270 views
  • 24 Jul, 2021
  • 251 locations
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare LOXO-305 to other drugs that work in a similar way that have

acalabrutinib
btk inhibitor
ibrutinib
cancer
measurable disease
  • 0 views
  • 18 Jun, 2021
  • 64 locations
Venetoclax Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of rituximab-lenalidomide in patients with relapsed/refractory MCL.

  • 3 views
  • 26 Jan, 2021
  • 22 locations
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

plus rituximab followed by standard PBSCT (dexamethasone, carmustine, cytarabine, etoposide, and melphalan [Dexa-BEAM]/TBI/high dose cyclophosphamide) in patients with untreated mantle cell

ara-c
cytarabine
vincristine
etoposide
cyclophosphamide
  • 134 views
  • 07 Nov, 2020
  • 2 locations
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)

  • 0 views
  • 30 Jul, 2021
  • 9 locations
Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma

refractory Mantle Cell Lymphoma (MCL) or who had sub-optimal response to standard therapy in the presence of TP53 mutation.

stem cell transplantation
direct bilirubin
neutrophil count
refractory mantle cell lymphoma
anthracyclines
  • 0 views
  • 24 Jan, 2021
  • 1 location
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

platelet count
tumor burden
bendamustine
rituximab
lenalidomide
  • 37 views
  • 26 Mar, 2021
  • 37 locations
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator-assessed failure-free survival.

bone marrow infiltration
ara-c
cytarabine
etoposide
cyclophosphamide
  • 64 views
  • 21 Jan, 2021
  • 80 locations